Outlook Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Dec 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 19, 2025
OTLK$0.46+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · September 30, | ||||||
| · · 2025 · · 2024 | ||||||
| Assets | | | | | | |
| Current assets: | | | | | | |
| Cash and cash equivalents | | $8,083,085 | | $14,927,538 | ||
| Accounts receivable | | | 1,490,931 | | | — |
| Inventory | | | 3,338,404 | | | — |
| Prepaid expenses and other current assets | | | 4,476,549 | | | 12,488,498 |
| Total current assets | | | 17,388,969 | | | 27,416,036 |
| | | | | | | |
| Operating lease right-of-use assets, net | | | 225,508 | | | 274,645 |
| Equity method investment | | | 552,183 | | | 693,190 |
| Other assets | | | 417,523 | | | 439,283 |
| Total assets | | $18,584,183 | | $28,823,154 | ||
| | | | | | | |
| Liabilities and stockholders’ deficit | | | | | | |
| | | | | | | |
| Current liabilities: | | | | | | |
| Current portion of unsecured convertible promissory note | | $29,947,000 | | $29,440,000 | ||
| Current portion of operating lease liabilities | | | 58,897 | | | 50,907 |
| Accounts payable | | | 10,192,388 | | | 7,968,725 |
| Accrued expenses | | | 5,314,320 | | | 3,237,468 |
| Income taxes payable | | | 302,000 | | | 1,856,629 |
| Total current liabilities | | | 45,814,605 | | | 42,553,729 |
| | | | | | | |
| Operating lease liabilities | | | 188,801 | | | 246,922 |
| Warrant liability | | | 4,768,438 | | | 59,099,013 |
| Total liabilities | | | 50,771,844 | | | 101,899,664 |
| | | | | | | |
| Commitments and contingencies (Note 9) | | | | | | |
| | | | | | | |
| Stockholders’ deficit: | | | | | | |
| Preferred stock, par value $0.01 per share: 10,000,000 shares authorized, no shares issued and outstanding | | | — | | | — |
| Common stock, par value $0.01 per share; 260,000,000 shares authorized; 53,887,233 and 23,905,635 shares issued and outstanding at September 30, 2025 and September 30, 2024, respectively | | | 538,873 | | | 239,057 |
| Additional paid-in capital | | | 572,983,229 | | | 469,969,333 |
| Accumulated deficit | | | (605,709,763) | | | (543,284,900) |
| Total stockholders' deficit | | | (32,187,661) | | | (73,076,510) |
| Total liabilities and stockholders' deficit | | $18,584,183 | | $28,823,154 | ||
See accompanying notes to consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.